Bullous pemphigoid (BP) is a chronic, autoimmune blistering disease that has concerning morbidity and mortality rates. Recently, several studies have focused on eosinophils due to their significant role in the pathogenesis of BP, considering that they are ubiquitous in the serum, tissue, and
blister fluids of patients with BP. With this context, precision
therapy that targets mediators of eosinophil activity could be a possible novel therapeutic strategy.
Interleukin (IL)-5 is crucial for B-cell maturation, which consequently results in
immunoglobulin production, and promotes eosinophil differentiation, proliferation, and activation. To our best knowledge,
reslizumab has not yet been reported to treat BP. Herein, we report a case of
steroid- and
omalizumab-resistant BP treated successfully using
reslizumab. Our data suggest that
IL-5 could be a novel specific
biologic target within the entire immunopathogenesis of BP, and
reslizumab would be a novel therapeutic modality.